UK Highlights Common Pitfalls In Safety Updates To Marketed Products
A senior MHRA official explained how companies can address deficiencies in their applications for making safety updates to approved medicines and prevent delays in providing updated information to health care professionals and patients.
You may also be interested in...
Saudi Arabia has explained what information on a drug’s review will be made public following a marketing authorization decision.
Revised labeling requirements for unauthorized investigational and auxiliary medicinal products under the EU Clinical Trial Regulation have been published in the Official Journal.
The European Medicines Agency has partnered with eight institutions having access to real-world healthcare data to enable its DARWIN EU project to deliver real-world evidence to the EU medicines regulatory network when needed.